OncoMatch/Clinical Trials/NCT05773859
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
Is NCT05773859 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies XP-DC vaccinations for epithelial ovarian cancer.
Treatment: XP-DC vaccinations — This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO IIIB, FIGO IIIC, FIGO IVA, FIGO IVB IF ONLY LYMPH NODES ≤ 1CM ABOVE THE DIAPHRAGM OR IN THE GROINS (FIGO)
Excluded: Stage FIGO I, FIGO IIB, FIGO IIIA, FIGO IVB WITH LIVER, SPLEEN OR LUNG METASTASES OR LYMPH NODES ABOVE THE DIAPHRAGM OR IN THE GROINS > 1 CM
Grade: high-gradelow grade
FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes ≤ 1cm above the diaphragm or in the groins; FIGO stage I-IIb, IIIa or IVb with liver, spleen or lung metastases or lymph nodes above the diaphragm or in the groins > 1 cm [excluded]
Performance status
WHO/ECOG 0–1
Demographics
Prior therapy
Lab requirements
Blood counts
Neutrophils >1.5x 10^9/L, platelets >100x 10^9/L, hemoglobin >5.6 mmol/L (9.0 g/dl)
Kidney function
estimated glomerular filtration rate > 45 ml/min/1.73m2
Liver function
AST/ALT <3 x ULN, serum bilirubin <1.5 x ULN (exception: Gilbert's syndrome is permitted)
Neutrophils >1.5x 10^9/L, platelets >100x 10^9/L, hemoglobin >5,6 mmol/L (9.0 g/dl), estimated glomerular filtration rate > 45 ml/min/1.73m2 , AST/ALT <3 x ULN, serum bilirubin <1.5 x ULN (exception: Gilbert's syndrome is permitted)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05773859 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage FIGO IIIB or FIGO IIIC or FIGO IVA or FIGO IVB IF ONLY LYMPH NODES ≤ 1CM ABOVE THE DIAPHRAGM OR IN THE GROINS is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages